The facility will be used to manufacture Eribulin, Eisai's experimental anti-cancer drug, once it receives regulatory approval.
-
An aerial view of the parenteral facility in the Research Technology Park,... -
The facility's operational launch is expected to strengthen Eisai's oncology... -
The facility will be used to manufacture Eribulin, Eisai's experimental...
Twitter